<article>California and Shanghai-based <a href="https://www.dealstreetasia.com/?s=Terns+Pharmaceuticals+Inc" target="_blank" rel="noopener">Terns Pharmaceuticals Inc</a> has closed an $80-million Series B funding round co-led by <a href="https://www.dealstreetasia.com/?s=Vivo+Capital" target="_blank" rel="noopener">Vivo Capital</a> and <a href="https://www.dealstreetasia.com/?s=OrbiMed" target="_blank" rel="noopener">OrbiMed</a>, according to an announcement.</article>

California and Shanghai-based <a href="https://www.dealstreetasia.com/?s=Terns+Pharmaceuticals+Inc" target="_blank" rel="noopener">Terns Pharmaceuticals Inc</a> has closed an $80-million Series B funding round co-led by <a href="https://www.dealstreetasia.com/?s=Vivo+Capital" target="_blank" rel="noopener">Vivo Capital</a> and <a href="https://www.dealstreetasia.com/?s=OrbiMed" target="_blank" rel="noopener">OrbiMed</a>, according to an announcement.
New investor Decheng Capital and return backer Lilly Asia Ventures also joined the round.
Terns Pharmaceuticals is focused on discovering and developing drugs to treat nonalcoholic steatohepatitis (NASH) and cancer.
&#8220;Their approach of adopting global or region-specific development strategies for advancing new clinical-stage therapeutics is unique, and Terns has made tremendous progress since they recently launched,&#8221; said OrbiMed managing partner Carl Gordon.
Terns president and CEO Weidong Zhong said the financing will help the company bring innovative therapeutics to underserved patients globally. The company said it is on track to enter the clinic for its lead programs TERN-101 and TERN-201 in the first half of 2019.
“The progress so far has put us one step closer to our goal of discovering effective and safe combination therapies for patients with NASH and liver fibrosis. We are grateful for the confidence and enthusiasm coming from our new and existing investors,” said Zhong.
Terns raised $30 million in a Series A round in April this year led by Lilly Asian Ventures.
Also Read:
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/sinovac-private-placement-china-101168/">Chinese drug developer Sinovac raises $87m in private placement</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/tot-biopharm-series-b-funding-104575/">Chengwei Capital-backed Tot Biopharm secures $102m Series B funding</a>

New investor Decheng Capital and return backer Lilly Asia Ventures also joined the round.

Pharma company Terns raises $80m Series B led by Vivo Capital, OrbiMed

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Pharma company Terns raises $80m Series B led by Vivo Capital, OrbiMed

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief